Alteogen to merge subsidiary Alteogen Biologics into parent company

Bitget2026/10/06 09:09

Alteogen will absorb wholly owned unit Alteogen Biologics, folding clinical, regulatory, marketing functions into a single biopharma operating structure. Merger ratio set at 1 Alteogen share to 0.1679581 shares for each Alteogen Biologics common share held. Alteogen expects 600,477 new common shares to be issued, about 0.86% dilution versus current shares outstanding. Closing targeted for Dec. 29, 2026; new shares slated to list on Jan. 25, 2027. Alteogen Biologics posted 2025 revenue of 8,312,613,191 won, net profit of 23,398,449,406 won, assets of 88,971,988,092 won. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alteogen Inc. published the original content used to generate this news brief via DART, the regulatory disclosure system operated by the South Korea Financial Supervisory Service (FSS) (Ref. ID: 20261006000420), on October 06, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.